Last reviewed · How we verify

primaquine (PQ) plus SP+AS

London School of Hygiene and Tropical Medicine · Phase 3 active Small molecule

Primaquine plus sulfadoxine-pyrimethamine and artesunate works by killing malaria parasites at multiple lifecycle stages, including the dormant liver forms that cause relapse.

Primaquine plus sulfadoxine-pyrimethamine and artesunate works by killing malaria parasites at multiple lifecycle stages, including the dormant liver forms that cause relapse. Used for Plasmodium vivax malaria with relapse prevention, Malaria transmission reduction and elimination.

At a glance

Generic nameprimaquine (PQ) plus SP+AS
SponsorLondon School of Hygiene and Tropical Medicine
Drug classAntimalarial combination therapy
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Primaquine is an 8-aminoquinoline that targets hypnozoites (dormant parasites in the liver) and gametocytes, preventing relapse and transmission. When combined with SP+AS (sulfadoxine-pyrimethamine plus artesunate), a synergistic antimalarial regimen is created: artesunate rapidly clears blood-stage parasites, while SP provides sustained schizontocidal activity, and primaquine eliminates the reservoir of latent parasites and sexual stages.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: